Zhang and colleagues conducted a placebo-controlled experiment to assess Saw Palmetto (Serenoa repens) extract's effectiveness and safety in treating chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
The scientists enrolled 221 individuals with CP/CPPS in a double-blind, randomized, placebo-controlled, multicenter, clinical study across 11 locations. Saw palmetto or a placebo was given to participants at random over a 12 weeks period. The change in overall score on the National Institutes of Health-Chronic Prostatitis Symptom Index served as the primary effectiveness outcome (NIH-CPSI).
The NIH-CPSI total score and sub-scores showed statistically significant improvements as compared to the placebo after saw palmettotreatment. After two weeks from the initial dose, the NIH-CPSI scores began to notice a considerable improvement, which persisted throughout the course of treatment. The study concluded that Saw palmetto was clinically superior to placebo for the treatment of CP/CPPS and was both safe and effective.
Zhang K, Guo RQ, Chen SW, Chen B, Xue XB, Chen S, Huang J, Liu M, Tian Y, Zuo L, Chen M, Zhou LQ. The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial. World J Urol. 2021 Sep;39(9):3489-3495. doi: 10.1007/s00345-020-03577-2. Epub 2021 Jan 16. PMID: 33452912; PMCID: PMC8510895.DRAFTJS_BLOCK_KEY:3j1j9